Detecting and predicting pre-eclampsia
AssigneePerkinElmer LAS, Inc.
InventorsLucilla Poston, Andrew Shennan
Life of this patent
Estimating the term…
Abstract
The technology described herein relates to methods of detecting or predicting pre-eclampsia (PE). The technology described herein also relates to commercial packages, such as diagnostic kits, for performing a method of detecting or predicting PE. In particular, the technology described herein provides methods of predicting pre-eclampsia when determining the levels of biochemical markers.
Claims30
A method of predicting pre-eclampsia (PE) comprising determining in a maternal sample obtained from a subject the level of soluble tissue necrosis factor alpha receptor 1 (sTNFRα1) and Matrix Metalloproteinase-9 (MMP-9).
A method of predicting pre-eclampsia (PE) comprising determining in a maternal sample obtained from a subject level of soluble tissue necrosis factor alpha receptor 1 (sTNFαR1) and placenta growth factor (PLGF), wherein a positive prediction is given when high sTNFαR1 level and low PLGF level are determined.
A diagnostic kit for performing the method of any one of the preceding claims,
- wherein the kit comprises reagents required to determine the level of the markers being measured, said markers selected from the group consisting of:
- placenta growth factor (PLGF),
- Matrix Metalloproteinase-9 (MMP-9),
- soluble tissue necrosis factor alpha receptor 1 (sTNFαR1), and
- plasminogen activation inhibitor 2 (PAI-2),
- plasminogen activation inhibitor 1 (PAI-1), and
- intracellular adhesion molecule-1 (ICAM).
Dependencies are inferred from the claim text.